A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

July 11, 2022

Study Completion Date

July 11, 2022

Conditions
Cervical Dystonia
Interventions
DRUG

ABP-450

ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.

DRUG

Placebo

0.9% sodium chloride, sterile, unpreserved, USP/Ph.Eur.

Trial Locations (21)

30329

Emory University, Atlanta

32792

Neurology One, Winter Park

33024

Infinity Clinical Research LLC, Hollywood

33176

The Neurology Research Group, Miami

33613

University of South Florida, Tampa

37232

Vanderbilt University Medical Center, Nashville

38157

Veracity Neuroscience LLC, Memphis

43054

The Orthopedic Foundation, New Albany

44195

The Cleveland Clinic Foundation, Cleveland

48334

Quest Research Institute - Hunt - PPDS, Farmington Hills

48824

Michigan State University, East Lansing

60612

Rush University Medical Center, Chicago

77030

Baylor College of Medicine, Houston

85032

Arizona Neuroscience Research, Phoenix

85258

Movement Disorder Center of Arizona, Scottsdale

87106

University of New Mexico, Albuquerque

89106

Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland

92354

Loma Linda University, Loma Linda

92708

Parkinson's and Movement Disorder Institute, Fountain Valley

93710

Neuro Pain Medical Center, Fresno

06905

New England Institute for Neurology and Headache, Stamford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

AEON Biopharma, Inc.

INDUSTRY

NCT04849988 - A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia | Biotech Hunter | Biotech Hunter